Middle East Study of Infections in Patients With Hematological Malignancies
NCT07900542
Summary
The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT) recipients across the Middle East. The objectives are to describe the epidemiological trends, identify risk factors for inappropriate antimicrobial therapy, and predictors of persistent BSI, microbiological relapse, and all-cause mortality. The study is entirely observational, participants will receive standard clinical care as directed by their treating doctors.
Eligibility
Inclusion Criteria: * Active underlying hematological malignancy or hematopoietic stem cell transplant recipient. * Bloodstream infection ( a blood culture yielding a growth of ≥1 micro-organism that is considered to be clinically significant and is actively treated by the attending physicians). Exclusion Criteria: * A bloodstream infection within 14 days of an already enrolled bloodstream infection, or at any time before resolution of active signs of infections associated with an already enrolled episode.
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07900542